89466-22-8

Basic information

• Product Name: N-(5-bromo-2-pyridinyl)methanesulfonamide
• Synonyms: N-(5-bromo-2-pyridinyl)methanesulfonamide;N-(5-bromo-2-pyridinyl)methanesulfonamide(SALTDATA: FREE);N-(5-bromo-2-pyridyl)methanesulfonamide;N-(5-bromopyridin-2-yl)methanesulfonamide;Methanesulfonamide,N-(5-bromo-2-pyridinyl)-
• CAS NO: 89466-22-8
• Molecular Formula: C₆H₇BrN₂O₂S
• Molecular Weight: 251.1
• Mol File: 89466-22-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 347.5 °C at 760 mmHg
• Flash Point: 163.9 °C
• Appearance: /
• Density: 1.802 g/cm³
• Vapor Pressure: 5.37E-05mmHg at 25°C
• Refractive Index: 1.626
• Storage Temp.: 2-8°C
• PKA: 5.74±0.10(Predicted)
• CAS DataBase Reference: N-(5-bromo-2-pyridinyl)methanesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-bromo-2-pyridinyl)methanesulfonamide(89466-22-8)
• EPA Substance Registry System: N-(5-bromo-2-pyridinyl)methanesulfonamide(89466-22-8)

Safety Data

• Hazardous Substances Data: 89466-22-8(Hazardous Substances Data)

Usage

General Description

N-(5-Bromo-2-pyridinyl)methanesulfonamide, also known as BPSA, is a chemical compound with the molecular formula C6H6BrN2O2S. It is a sulfonamide derivative, which makes it an organic compound containing a sulfur atom bonded to an amine group, and it also contains a bromine atom bonded to a pyridine ring. BPSA is often used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and dyes. It has also been studied for its potential antimicrobial and anticancer properties. Additionally, it is an important reagent in organic chemistry for the formation of carbon-sulfur bonds. BPSA is considered to be a valuable building block in the field of medicinal chemistry and chemical synthesis.

InChI:InChI=1/C6H7BrN2O2S/c1-12(10,11)9-6-3-2-5(7)4-8-6/h2-4H,1H3,(H,8,9)

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 7143-01-3 Methanesulfonic anhydride 
• 124-63-0 methanesulfonyl chloride 

Relevant articles and documents

Design, synthesis, and biological evaluation of novel Bcr-AblT315I inhibitors incorporating amino acids as flexible linker

Despite the success of imatinib in CML therapy through Bcr-Abl inhibition, acquired drug resistance occurs over time in patients. In particular, the resistance caused by T315I mutation remains a challenge in clinic. Herein, we embarked on a structural optimization campaign aiming at discovery of novel Bcr-Abl inhibitors toward T315I mutant based on previously reported dibenzoylpiperazin derivatives. We proposed that incorporation of flexible linker could achieve potent inhibition of Bcr-AblT315I by avoiding steric clash with bulky sidechain of Ile315. A library of 28 compounds with amino acids as linker has been developed and evaluated. Among them, compound AA2 displayed the most potent activity against Bcr-AblWT and Bcr-AblT315I, as well as toward Bcr-Abl driven K562 and K562R cells. Further investigations indicated that AA2 could induce apoptosis of K562 cells and down regulate phosphorylation of Bcr-Abl. In summary, the compounds with amino acid as novel flexible linker exhibited certain antitumor activities, providing valuable hints for the discovery of novel Bcr-Abl inhibitors to overcome T315I mutant resistance, and AA2 could be considered as a candidate for further optimization.

PI3K inhibitor, preparation method and application thereof in pharmacy

The invention belongs to the technical field of pharmaceuticals and particularly relates to a PI3K inhibitor, a preparation method and application thereof in the pharmacy. The PI3K inhibitor is a compound of the structure shown by the general formula I or medically acceptable salt of the inhibitor. After the PI3K inhibitor is tested with a PI3K biochemical activity test method, the compound has excellent inhibitory activity to PI3K alpha and PI3K gamma, wherein the IC50 values of a plurality of compounds to the PI3K alpha and PI3K gamma reach nanomole grades (smaller than 100 nM). The result shows that the compounds can provide the inhibitor with better effectiveness and selectivity for curing PI3K-acted proliferative disease, and further a targeted drug for curing No. I type diabetes mellitus, lung disease, breast cancer, prostatic cancer, solid tumor, lymphoma, cardiovascular disease, rheumatoid arthritis, leukemia and the like can be hopefully developed. (Please see the general formula I in the description.).

A practical source of chlorodifluoromethyl radicals. Convergent routes to gem -difluoroalkenes and -dienes and (2,2-Difluoroethyl)-indoles, -azaindoles, and -naphthols

The preparation of O-octadecyl-S-chlorodifluoromethyl xanthate from chlorodifluoroacetic acid and its use as a convenient source of chlordifluoromethyl radicals is described. This reagent may be used to access gem-difluoroalkenes and -dienes, as well as (2,2-difluoroethyl)indolines, -indoles, and -naphthols.